Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Moderate Buy consensus from 10 brokerages — analysts break down as 2 sells, 6 buys and 2 strong buys, with an average 12‑month price target of $50.57.
• Sionna shares opened at $45.09 (12‑month range $9.24–$46.10) and the company reported EPS of ($0.46), beating estimates of ($0.61), with a market cap of about $2.03 billion.
• Significant insider selling: major shareholder TPG sold 250,000 shares (~$10.0M) and insiders have sold 311,906 shares (~$12.76M) in the past 90 days; insiders still own about 3.9% of the stock.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $50.5714.

SION has been the subject of several research analyst reports. Lifesci Capital raised shares of Sionna Therapeutics to a "strong-buy" rating in a report on Wednesday, February 25th. Raymond James Financial reissued a "strong-buy" rating and issued a $53.00 price target on shares of Sionna Therapeutics in a report on Monday, January 5th. Citizens Jmp initiated coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They issued a "market outperform" rating and a $63.00 price target for the company. Citigroup initiated coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They issued an "outperform" rating for the company. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Sionna Therapeutics in a report on Monday, December 29th.

Sionna Therapeutics Stock Up 4.1%

Shares of SION stock opened at $45.09 on Thursday. Sionna Therapeutics has a 12-month low of $9.24 and a 12-month high of $46.10. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -23.12 and a beta of 3.01. The firm has a fifty day moving average of $37.40 and a 200-day moving average of $38.18.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.15.

Insider Buying and Selling

In related news, major shareholder Tpg Gp A, Llc sold 250,000 shares of the company's stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total value of $10,000,000.00. Following the completion of the transaction, the insider directly owned 6,494,962 shares of the company's stock, valued at approximately $259,798,480. This represents a 3.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Orbimed Advisors Llc sold 29,063 shares of the company's stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the completion of the transaction, the director directly owned 3,530,702 shares of the company's stock, valued at approximately $157,398,695.16. The trade was a 0.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 311,906 shares of company stock valued at $12,759,732. Company insiders own 3.90% of the company's stock.

Hedge Funds Weigh In On Sionna Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SION. Russell Investments Group Ltd. acquired a new position in Sionna Therapeutics in the 3rd quarter worth $30,000. BNP Paribas Financial Markets acquired a new position in Sionna Therapeutics in the 2nd quarter worth $31,000. GF Fund Management CO. LTD. acquired a new position in Sionna Therapeutics in the 4th quarter worth $36,000. Balyasny Asset Management L.P. acquired a new position in Sionna Therapeutics in the 4th quarter worth $58,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Sionna Therapeutics in the 4th quarter worth $89,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.